Oligonucleotide Synthesis Market Overview

The oligonucleotide synthesis market is presently characterized by the presence of both niche, specialty oligonucleotide synthesis companies, focused on early-stage development and production (preclinical and / or clinical scales), and one-stop-shops, which have, over time, acquired an extensive range of capabilities to cater to essentially all the product development and commercialization requirements of sponsors.

The global oligonucleotide synthesis market size is estimated to be worth $ 4.8 billion in 2024 and is expected to grow at compounded annual growth rate (CAGR) of 9.9% during the forecast period 2024-2035.

About 18,043 patients in Oligonucleotide Synthesis Market domain were observed to be enrolled in trials conducted in North America, accounting for about 23% of the overall enrolled patient population. Within North America, close to 90% of the aforementioned patients were enrolled at different sites in the US (15,630). It is worth highlighting that 152 clinical trials related to oligonucleotide therapeutics are completed; this is followed by 63 clinical trials that are currently recruiting patients. Further, 59 trials are currently active and not recruiting patients. In terms of trial phase, 46% of registered trials of oligonucleotide-based therapies are in phase II, followed by 35%  in phase I.

There are around 64 partnerships that have been inked by various stakeholders engaged in the oligonucleotide synthesis market, during the period 2014-2023 (till September). It is worth noting that in 2023, 34% of partnerships were acquisitions which emerged as the most popular type of partnership model adopted by players engaged in the oligonucleotide synthesis domain. This can be attributed to the incessant efforts of players to further advance the development of their oligonucleotide products. This is followed by 16% of manufacturing agreements and 14% of  service alliances. Since 2017, more than 55 deals have been inked between various stakeholders engaged in this domain and acquisitions emerged as the most common type of partnership model.

In order to accommodate their growing businesses, contract manufacturers are heavily investing in either expanding their existing facilities / capabilities or construct / acquire new facilities in other geographies. Close to 60 expansion initiatives  have been undertaken in the oligonucleotide synthesis industry, during the period 2015-2023, majority of which were reported during the period 2021. This can be attributed to the indubitably rising demand for oligonucleotides in the COVID-19 pandemic.

Oligonucleotide Synthesis Market Key Companies

Examples of key oligonucleotide synthesis companies include Agilent Technologies, Ajinomoto Bio-Pharma Services, CordenPharma, Creative Biolabs, Ella Biotech, Eurofins Genomics, Future synthesis, Integrated DNA Technologies, Kaneka Eurogentec, LGC Biosearch Technologies, Microsynth, Nitto Avecia, Merck, Ribo Biotechnology, STA Pharmaceutical, Sumitomo Chemical, Thermo Fisher Scientific, TriLink Biotechnologies. 

Moreover, 33% of the companies in this domain have expanded their facilities for the synthesis of oligonucleotides at clinical scale only, followed by 29% of those undertaking such initiatives for the production of oligonucleotides at preclinical, clinical and commercial scales of operation; notable examples of such service providers (in alphabetical order) include Dalton Pharma Services, EUROAPI, Nitto Avecia and WuXi STA. To keep pace with the growing demand for oligonucleotides, companies have made elaborate investments to expand their existing capacities and capabilities; this trend is most pronounced in the US and China.

Browse Complete Report at: https://www.rootsanalysis.com/reports/oligonucleotide-synthesis/304.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture catalysts, and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organizations worldwide.

All our analysts are trained to produce high-quality research work. They are continuously mentored by senior experts to present an original, unbiased and informed perspective on pressing issues in the industry. On any particular subject, we bring together the best available resources to ensure highest quality in all our reports.

Contact Details

Roots Analysis 

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.chaudhary@rootsanalysis.com 

Website: https://www.rootsanalysis.com/